Brain investigation and brain conceptualization

Functional Neurology

Volumn 28, Issue 3, 2013, Pages 175-190

  Redolfi, Alberto ^a   Bosco, Paolo ^a   Manset, David ^b   Frisoni, Giovanni B ^a  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b Gnúbila France ^*  (France)

Author keywords

Alzheimer's disease; Hypermodel; Multimodal integration; Multiscale approach

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; HOMOTAURINE; PRESENILIN 1; PRESENILIN 2; TARENFLURBIL; TAU PROTEIN;

AGE; ALZHEIMER DISEASE; ARTICLE; BAYES THEOREM; BIOINFORMATICS; BRAIN ATROPHY; BRAIN HYPERMODEL; BRAIN INJURY; BRAIN SIZE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC DISORDER; GENOMICS; IMAGE PROCESSING; MILD COGNITIVE IMPAIRMENT; MULTIVARIATE ANALYSIS; NEUROBIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTEOMICS; PROTON NUCLEAR MAGNETIC RESONANCE; RISK FACTOR; TEMPORAL LOBE; THEORETICAL MODEL; ATROPHY; BIOLOGICAL MODEL; BIOLOGY; BRAIN; COMPUTER SIMULATION; HUMAN; NERVOUS SYSTEM DISEASES; PATHOLOGY; PATHOPHYSIOLOGY; PSYCHOLOGY;

ALZHEIMER DISEASE; ATROPHY; BIOLOGICAL MARKERS; BRAIN; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; HUMANS; MODELS, NEUROLOGICAL; NERVOUS SYSTEM DISEASES;

EID: 84886933057     PISSN: 03935264     EISSN: 19713274     Source Type: Journal    
DOI: 10.11138/FNeur/2013.28.3.175     Document Type: Article

References (73)

1. Alzheimer A, Stelzmann RA, Schnitzlein HN, et al (1995). An English translation of Alzheimer's 1907 paper, Uber eine eigenartige Erkankung der Hirnrinde. Clin Anat 8: 429-431.
2. Antila K, Lötjönen J, Thurfjell L, et al (2013). The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer's disease. Interface Focus 3: 20120072
3. Astarita G, Piomelli D (2011). Towards a whole-body systems [multi-organ] lipidomics in Alzheimer's disease. Prostaglandins Leukot Essent Fatty Acids 85:197-203.
4. Barreto P de S (2013). Alzheimer's disease: learning from the past, looking to the future. Am J Alzheimers Dis Other Demen 28: 304-305.
5. Bencherif B, Endres CJ, Musachio JL, et al (2002). PET imaging of brain acetylcholinesterase using [11C]CP-126,998, a brain selective enzyme inhibitor. Synapse 45: 1-9.
6. Bernal-Rusiel JL, Greve DN, Reuter M, et al (2012). Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models. Neuroimage 66C: 249-260.
7. Blennow K, Zetterberg H (2013). The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. Med Clin North Am 97: 369-376.
8. Calimera A, Macii E, Poncino M (2013) The Human Brain Project and neuromorphic computing. Funct Neurol 28:191-196.
9. Chaari L, Pesquet J.-C., Tourneret J.-Y., et al (2010). A hierarchical Bayesian model for frame representation. IEEE Transactions on Signal Processing 58: 5560-5571.
10. Clark CM, Pontecorvo MJ, Beach TG, et al (2012). Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 11: 669-678.
11. Cordonnier C, van der Flier WM (2011). Brain microbleeds and Alzheimer's disease: innocent observation or key player? Brain 134: 335-344.
12. D'Angelo E, Solinas S, Garrido J, et al (2013). Realistic modeling of neurons and networks: towards brain simulation. Funct Neurol 28:153-166.
13. Dinov ID, Van Horn JD, Lozev KM, et al (2009). Efficient, distributed and interactive neuroimaging data analysis using the LONI pipeline. Front Neuroinform 3:22.
14. Egerházi A, Berecz R, Bartók E, et al (2007). Automated Neuropsychological Test Battery (CANTAB) in mild cognitive impairment and in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 31:746-751.
15. Ewers M, Frisoni GB, Teipel SJ, et al (2011). Staging Alzheimer's disease progression with multimodality neuroimaging. Prog Neurobiol 95: 535-546.
16. Fischl B (2012). FreeSurfer. NeuroImage 62: 774-781.
17. Flicek P, Ahmed I, Amode MR, et al (2013). Ensembl 2013. Nucleic Acids Res 41 (Database issue): D48-55.
18. Fox NC, Warrington EK, Freeborough PA, et al (1996). Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 119: 2001-2007.
19. Frisoni GB, Fox NC, Jack CR Jr, et al (2010). The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6:67-77.
20. Frisoni GB, Redolfi A, Manset D, et al (2011). Virtual imaging laboratories for marker discovery in neurodegenerative diseases. Nat Rev Neurol 7: 429-438.
21. Frisoni GB, Winblad B, O'Brien JT (2011). Revised NIA-AA criteria for the diagnosis of Alzheimer's disease: a step forward but not yet ready for widespread clinical use. Int Psychogeriatr 23: 1191-1196.
22. Friston KJ (1995). Commentary and opinion: II. Statistical parametric mapping: ontology and current issues. J Cereb Blood Flow Metab 15: 361-370.
23. Friston KJ, Glaser DE, Henson RN, et al (2002a). Classical and Bayesian inference in neuroimaging: applications. Neuroimage 16: 484-512.
24. Friston KJ, Penny W, Phillips C, et al (2002b). Classical and Bayesian inference in neuroimaging: theory. Neuroimage 16: 465-483.
25. Furukawa K, Okamura N, Tashiro M, et al (2010). Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET. J Neurol 257: 721-727.
26. Genovese CR, Lazar NA, Nichols T (2002). Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 15: 870-878.
27. George-Hyslop PS, Rossor M (2001). Alzheimer's disease. Unravelling the disease process. Lancet 358 Suppl: S1.
28. Graff-Radford J, Kantarci K (2013). Magnetic resonance spectroscopy in Alzheimer's disease. Neuropsychiatr Dis Treat 9: 687-696.
29. Hampel H, Teipel SJ, Fuchsberger T, et al (2004). Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 9:705-710.
30. Herholz K, Westwood S, Haense C, et al (2011). Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. J Nucl Med 52: 1218-1226.
31. Herskovits EH, Peng H, Davatzikos C (2004). A Bayesian morphometry algorithm. IEEE Trans Med Imaging 23: 723-737.
32. Hochberg Y, Benjamini Y (1990). More powerful procedures for multiple significance testing. Stat Med 9: 811-818.
33. Jack CR Jr (2012). Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology 263: 344-361.
34. Jack CR Jr, Knopman DS, Jagust WJ, et al (2013). Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12: 207-216.
35. Jack CR Jr, Knopman DS, Jagust WJ, et al (2010). Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119-128.
36. Jack CR Jr, Knopman DS, Weigand SD, et al (2012). An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 71:765-775.
37. Jack CR Jr, Lowe VJ, Senjem ML, et al (2008). 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131: 665-680.
38. Johansson P, Mattsson N, Hansson O, et al (2011). Cerebrospinal fluid biomarkers for Alzheimer's disease: diagnostic performance in a homogeneous mono-center population. J Alzheimers Dis 24:537-546.
39. Karran E, Mercken M, De Strooper B (2011).The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev.Drug Discov 10: 698-712.
40. Kim JS, Singh V, Lee JK, et al (2005). Automated 3-D extraction and evaluation of the inner and outer cortical surfaces using a Laplacian map and partial volume effect classification. Neuroimage 27: 210-221.
41. Klunk WE (2011) Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging 32 (Suppl 1): S20-36.
42. Klunk WE, Mathis CA (2008). The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr Opin Neurol 21:683-687.
43. Leung KK, Barnes J, Modat M, et al (2011). Brain MAPS: an automated, accurate and robust brain extraction technique using a template library. Neuroimage 55:1091-1108.
44. Leung KK, Ridgway GR, Ourselin S, et al (2012). Consistent multi-time-point brain atrophy estimation from the boundary shift integral. Neuroimage 59: 3995-4005.
45. López-Arrieta JM, Schneider L (2006) Metrifonate for Alzheimer's disease. Cochrane Database Syst Rev (2):CD003155.
46. Lötjönen J, Wolz R, Koikkalainen J, et al (2011). Fast and robust extraction of hippocampus from MR images for diagnostics of Alzheimer's disease. Neuroimage 56: 185-196.
47. Mangialasche F, Solomon A, Winblad B, et al (2010). Alzheimer's disease: clinical trials and drug development. Lancet Neurol 9:702-716.
48. Markram H (2013) Seven challenges for neuroscience. Funct Neurol 28:145-151.
49. McKhann GM, Knopman DS, Chertkow H, et al (2011). The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:263-269.
50. Mullikin JC, Hunt SE, Cole CG, et al (2000). An SNP map of human chromosome 22. Nature 407: 516-520.
51. Nathoo FS, Lesperance M, Lawson A, et al (2012). Comparing variational Bayes with Markov chain Monte Carlo for Bayesian computation in neuroimaging. Stat Methods Med Res 22: 398-423.
52. Nichols TE, Holmes AP (2002) Nonparametric permutation tests for functional neuroimaging: a primer with examples. Human Brain Mapp 15: 1-25.
53. Pepe MS, Feng Z, Janes H, et al (2008). Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100:1432-1438.
54. Petersen RC (2012) New clinical criteria for the Alzheimer's disease spectrum. Minn Med 95: 42-45.
55. Petrella JR, Mattay VS, Doraiswamy PM (2008) Imaging genetics of brain longevity and mental wellness: the next frontier? Radiology 246: 20-32.
56. Pillai JA, Cummings JL (2013) Clinical trials in predementia stages of Alzheimer disease. Med Clin North Am 97: 439-457.
57. Qizilbash N, Birks J, Lopez Arrieta J, et al (2007). WITH-DRAWN: Tacrine for Alzheimer's disease. Cochrane Database Syst Rev (3):CD000202.
58. Ramanan VK, Risacher SL, Nho K, et al (2013). APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol Psychiatry doi: 10.1038/mp.2013.19.
59. Ridha BH, Barnes J, Bartlett JW, et al (2006). Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 5: 828-834.
60. Roberson ED, Mucke L (2006). 100 years and counting: prospects for defeating Alzheimer's disease. Science 314: 781-784.
61. Scheinin NM, Aalto S, Koikkalainen J, et al (2009). Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 73: 1186-1192.
62. Shin J, Kepe V, Barrio JR, et al (2011). The merits of FDDNPPET imaging in Alzheimer's disease. J Alzheimers Dis 26 (Suppl 3):135-145.
63. Silvestri L, Sacconi L, Pavone FS (2013). The connectomics challenge. Funct Neurol 28:167-173.
64. Smith AD (2002). Imaging the progression of Alzheimer pathology through the brain. Proc Natl Acad Sci U S A 99: 4135-4137.
65. Soininen H, Mattila J, Koikkalainen J, et al (2012). Software tool for improved prediction of Alzheimer's disease. Neurodegener Dis 10: 149-152.
66. Sperling R, Johnson K (2013). Biomarkers of Alzheimer disease: current and future applications to diagnostic criteria. Continuum (Minneap Minn) 19: 325-338.
67. Teipel SJ, Sabri O, Grothe M, et al (2013). Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease. J Alzheimers Dis 33 (Suppl 1): S329-347.
68. Vellas B, Aisen PS (2010). Early Alzheimer's trials: new developments. J Nutr Health Aging 14: 293.
69. Vercauteren T, Pennec X, Perchant A, et al (2009). Diffeomorphic demons: efficient non-parametric image registration. Neuroimage 45, (1 Suppl): S61-72.
70. Wakefield J, De Vocht F, Hung RJ (2010). Bayesian mixture modeling of gene-environment and gene-gene interactions. Genetic Epidemiol 34:16-25.
71. Wolz R, Aljabar P, Hajnal JV, et al (2010). LEAP: learning embeddings for atlas propagation. Neuroimage 49: 1316-1325.
72. Woolrich MW, Jbabdi S, Patenaude B, et al (2009). Bayesian analysis of neuroimaging data in FSL. Neuroimage 45 (1Suppl): S173-186.
73. Zhang H, Awate SP, Das SR, et al (2010). A tract-specific framework for white matter morphometry combining macroscopic and microscopic tract features. Med Image Anal 14: 666-673.